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Abstract 
 
The overall goal of this project was to accurately predict the time to death for patients 
with sepsis in Uganda using markers involved in the endothelial response to infection. 
There is substantial evidence from developed countries that endothelial markers 
measured at the time of hospital admission are associated with increased risk of death 
within 28 days, and we hypothesized that they would also discriminate between patients 
who die shortly after admission from those who have slower clinical progression.  
We first investigated the underlying heterogeneity in sepsis. We hypothesized that 
patients presenting with severe sepsis represent a mixture of latent processes and 
subgroups of individuals that can be grouped by their “endothelial response profile”. We 
characterized the underlying processes and subgroups using latent factor analysis (LFA) 
and latent profile analysis (LPA), respectively. We then identified biomarkers that 
accurately predict which patients will die by examining the discriminative value of the 
candidate predictors. Biomarkers and patient characteristics with the highest predictive 
accuracy were used to model the relative time to death using a generalized gamma model.  
The LFA results suggested four latent processes, interpreted as “inflammation”, “vessel 
stability”, “leukocyte recruitment”, and “vessel instability” based on the known biologic 
functions of the constituent biomarkers. Using LPA, we identified three subgroups of 
patients with endothelial response patterns that were homogenous within the group and 
distinct from the other groups. The patterns were interpreted as “quiescent”, “endothelial 
dysfunction”, and “endothelial repair”. Death by 28 days was best predicted with a model 
consisting of endothelial dysfunction, CD4
+
 T cell count less than 50 cells/mm
3
, 
 iii 
Karnofsky score of 20 or less, and the 5
th
 quintile of sFlt-1 concentration, a soluble 
receptor involved in vascular leak. The area under the curve (AUC) for the model for 28-
day mortality was 0.73 in the derivation set and 0.77 in the validation set. The survival 
time for patients with endothelial dysfunction was approximately half that of patients 
with similar CD4
+
 T cell counts, Karnofsky scores, and sFlt-1 concentrations (relative 
time = 0.49, 95%CI: 0.32, 0.75). Profiling patients based on their endothelial response 
may provide a clinically meaningful way to categorize patients into homogenous 
subgroups and may identify patients at risk of imminent death. 
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I. Introduction 
What is sepsis? 
Sepsis is defined as a systemic inflammatory syndrome in response to an infection 
(probable or documented), and is classified as severe when accompanied by evidence of 
hypoperfusion or acute organ dysfunction.
1
 The criteria for systemic inflammation are 
based on temperature, heart rate, respiratory rate, and white blood cell count, and can 
occur in both infectious and non-infectious conditions. Severe sepsis accompanied by 
hypotension that is refractory to adequate fluid resuscitation constitutes septic shock. This 
broad framework of definitions was proposed in the American College of Chest 
Physicians and Society of Critical Care Medicine Consensus Conference in 1991.
2
 The 
definition of sepsis was modified in a Consensus Conference in 2001,
3
 to include 
additional clinical and laboratory parameters (Appendix 1).  
Sepsis is caused by a pathogenic host response to a wide range of microorganisms, 
including bacteria, viruses, fungi and parasites. The infecting pathogen is often not 
identified.
4
 In developed countries the majority of infections are bacterial, with gram-
negative infections (62.2%) slightly more frequent than gram-positive infections 
(46.8%).
5
 The predominant organisms typically isolated include Staphylococcus aureus, 
Pseudomonas species, Escherichia coli, and Candida species. Very limited data exist on 
the etiology of sepsis in developing countries. A recent systematic review of community 
acquired bloodstream infections in Africa found Salmonella species (42.3%), Brucella 
species (13.2%), Streptococcus pneumoniae (9.5%), and Staphylococcus aureus (5.4%) 
as the predominant organisms isolated from adults.
6
  
 2 
Sepsis can originate from a range of sites of infection, with the respiratory tract, 
genitourinary tract, and abdomen the most frequent sites.
5
 The pathogen, pathogen load, 
site of infection, and host susceptibility contribute to the clinical presentation and course 
of disease. The signs and symptoms are highly variable and typically non-specific. The 
clinical spectrum can range from minor signs and symptoms such as fever, elevated heart 
rate, and altered mental status, to severe illness with organ dysfunction, shock, and death.  
The broad definition of sepsis combines a wide range of pathogens and sites of infection 
into one complex syndrome with substantial heterogeneity. The underlying assumption is 
that the host response to the infectious insult is consistent across the spectrum of 
pathogens and affected organ systems. The failure to develop effective therapeutics and 
the limited success in developing diagnostic or prognostic tests is often attributed to the 
heterogeneity inherent in the syndrome.
7,8
 There are currently no Food and Drug 
Administration (FDA) approved treatments for sepsis, despite several decades of clinical 
trials. Activated protein C was FDA approved but then removed from the market after 
further studies failed to demonstrate a treatment effect. Restricting the evaluation of 
candidate therapeutics to homogeneous subsets of patients, such as patients with a 
specific infectious etiology, has been proposed.
7,9
 However, despite widespread 
recognition that the pathogenic processes leading to organ failure and death differ 
between microorganisms, most clinical trials continue to group together all patients with 
sepsis.
8
 Furthermore, given the wide spectrum of pathogens causing sepsis, powering 
studies for a specific organism would be challenging. 
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The host response 
Sepsis is conceptualized as a pathogenic host response to a microorganism. Researchers 
concluded that the host response, rather than the direct effects of the microorganism, was 
pathogenic because many patients with sepsis die despite clearance of the infection.
10,11
 
The striking clinical presentation of patients with sepsis, often consisting of high fever, 
shock, and respiratory failure, contributed to the theory that sepsis was due to an 
uncontrolled inflammatory response.
12
 Attention initially focused on excessive 
inflammation, and many clinical trials of immunosuppressive therapies were conducted. 
In particular, the efficacy of corticosteroid treatment on reducing 28-day mortality was 
thoroughly investigated. A recent systematic review and meta-analysis found that 
corticosteroid treatment did not improve 28-day mortality; however, analysis of a 
subgroup of trials of prolonged low-dose treatment found a small reduction in mortality.
13
 
After more than 30 clinical trials of various immunosuppressive therapies failed, the idea 
of a “compensatory anti-inflammatory response syndrome” (CARS) that followed the 
initial pro-inflammatory response was introduced.
14
 The current thinking recognizes a 
complex response consisting of both proinflammatory and anti-inflammatory 
mechanisms, as well as dysfunction of the vascular endothelium.
11
  
 
Inflammation and immunosuppression 
The initial host response to an infection consists of activation of pattern recognition 
receptors, particularly toll-like receptor (TLR)2 and TLR4 for bacterial infections. TLR 
activation initiates a signaling cascade through NF-κB, resulting in release of 
 4 
proinflammatory cytokines and chemokines, such as interleukin (IL)-1α, IL-1β, IL-6, IL-
8 and tumor necrosis factor –alpha (TNFα).
15
 Release of these cytokines is necessary for 
a normal, effective immune response against a pathogen. However, excessive production 
is associated with sepsis
16,17
 and the development of organ dysfunction and death.
18,19
 
Subsequent studies found concentrations of anti-inflammatory cytokines such as IL-10 
were also elevated in patients with septic shock versus sepsis alone
20
, and the 
concentrations were significantly higher in patients who died.
21,22
 A recent review 
summarized that patients with sepsis typically followed one of three patterns of cytokine 
responses: 1) rapid production of both proinflammatory and anti-inflammatory cytokines, 
2) predominance of anti-inflammatory cytokines, or 3) globally depressed production of 
cytokines.
12
  
There is substantial evidence that patients who survive the initial hyper-inflammatory 
phase of sepsis enter an immunosuppressed phase. Patients with severe sepsis in intensive 
care units (ICUs) are at increased risk for nosocomial opportunistic infections, such as 
Candida spp, Pseudomonas spp, and Klebsiella pneumoniae spp.
12,23
 Otto et. al found 
that the percent of blood cultures positive for an opportunistic bacteria was 9.1% in the 
first phase of sepsis (days 1-5 of hospitalization), versus 17.8% in the late phase of sepsis 
(beginning day 16).
23
 The investigators also found 12.6% of blood cultures positive for 
Candida spp in the first phase versus 30% in the late phase. However, this study did not 
have a non-septic comparison group, so it is difficult to attribute the observed increase to 
sepsis versus the inherent risk of nosocomial infection in the ICU. A recent study 
conducted by Boomer et. al harvested spleens and lung tissue postmortem from patients 
who died from severe sepsis and critically ill controls within 30-180 minutes of death.
24
 
 5 
The investigators stimulated the cells and examined the cytokine secretion (TNF, 
interferon [IFN]-γ, IL-6, and IL-10) and used flow cytometry to examine cell surface 
receptor-ligand expression profiles. Cytokine secretion in patients with severe sepsis was 
less than 10% that in controls, controlling for age, duration of illness, corticosteroid use, 
and nutritional status. In addition, they demonstrated depletion of CD4+ T cells, CD8+ T 
cells, and HLA-DR cells on splenocytes isolated from patients with severe sepsis, and 
increased percentages of inhibitory receptor ligands on lung epithelial cells.
24
 
Collectively these studies support the theory of an immunosuppressive phase in sepsis. 
 
Microcirculatory alterations 
Sepsis is characterized by microvascular leak, which manifests clinically as hypotension, 
tissue edema, hypoperfusion, and organ dysfunction.
25,26
 The vascular leak resulting from 
endothelial activation is thought to contribute to the tissue hypoxia and organ dysfunction 
that are integral to the pathogenesis of sepsis. Compared to ICU controls, the capillaries 
of patients with severe sepsis have decreased or intermittent flow as well as decreased 
vascular density.
25
 Several mechanisms have been proposed to account for the 
microcirculatory alterations, including endothelial dysfunction.
25
  
This project evaluates several biomarkers involved in the endothelial response to sepsis, 
including angiopoietin-1 (Ang-1) and Ang-2, soluble Tie-2 receptor (sTie-2R), vascular 
endothelial growth factor (VEGF), and fms-like tyrosine kinase-1 (sFLT-1), markers of 
inflammation (Chi3L1, IP-10, TREM-1, and ICAM), and molecules involved in 
 6 
coagulation, including von Willebrand factor (vWF) and platelet factor 4 (PF4). The role 
of these biomarkers in sepsis is shown in Table 1.  
 
 
Biomarker Role in Sepsis 
Angiopoietin-1 (Ang1) Inhibits endothelial activation through VEGF and NF-
κB signaling pathways, enhances endothelial barrier 
function
26
 
Angiopoietin-2 (Ang2) Opposes Ang1, stimulates vascular leak and endothelial 
cytoskeleton rearrangement
26
 
Tie-2 Receptor (sTie-2R) Receptor for Ang1 and Ang2
26
 
Vascular endothelial growth factor (VEGF) Stimulates vascular leak,
8
 hypoxia inducible mitogen
28
  
fms-like tyrosine kinase-1 (sFLT-1) Soluble receptor for VEGF, inhibits VEGF signaling, 
may lead to immune suppression
27
 
Chitinase-3 like protein-1 (Chi3L1) Elevated in inflammation or ongoing fibrosis 
Interferon –inducible protein 10 (IP-10) Regulates lymphocyte trafficking
29
 
Triggering receptor expressed on myeloid 
cells type 1 (TREM1) 
Amplifies the inflammatory response 
Intracellular adhesion molecule-1 (ICAM-1) Indicator of endothelial activation, role in initiation of 
inflammation
28
 
von Willebrand factor (vWF) Ultra-large vWF multimers cause platelet clot 
formation
28
 
Platelet factor 4 (PF4) Promotes blood coagulation, released following platelet 
activation, (aka chemokine CXCL4)
30
 
Table 1. Role of biomarkers in sepsis 
 
The endothelium is a monolayer of cells lining of the interior surface of blood vessels 
that acts as a selective barrier to control the passage of fluids, electrolytes, proteins and 
cells into and out of the bloodstream. During the course of an infection the endothelium 
becomes activated, meaning that it is more prone to clots, there is increased 
transmigration of leukocytes to sites of infection, and the vessels become leaky.
26
 
Adhesion molecules, such as intercellular adhesion molecule (ICAM)-1, are expressed by 
the endothelial cells and bind to ligands on leukocytes in the bloodstream to slow and 
eventually stop the cells so they can migrate into the underlying tissue. While essential 
for an effective defense against invading pathogens, extravasation of leukocytes across 
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the endothelium can result in tissue damage when cytotoxic mediators are released.
31
  
Neutrophils and monocytes express high levels of a receptor called triggering receptor 
expressed on myeloid cells (TREM)–1 in extracellular bacterial infections. TREM-1 
triggers secretion of potent proinflammatory mediators.
32
 Lymphocytes are also recruited 
to the site of infection through molecules such as interferon inducible protein 10 (Ip10).
29
 
Lymphocytes have been shown to promote systemic inflammation in septic shock, and 
lymphocyte activation is associated with development of multi-organ failure.
29
 Immune 
cells such as neutrophils and macrophages also secrete factors including chitinase-3 like 
protein-1 (Chi3L1) to further stimulate inflammation and promote remodeling.
33
 Platelet 
factor 4 (PF4) is secreted by activated platelets, and plays a role in coagulation.
30
 PF4 has 
also been found to inhibit angiogenesis, the formation of new blood vessels from pre-
existing blood vessels.   
Activation of the endothelium leads to the expression of adhesion molecules, and release 
of proteins including angiopoietin (ang)-2 and von Willebrand factor (vWF) into the 
bloodstream.
34
 Ang-2 is a growth factor, which competes with ang-1 for their receptor, 
tyrosine kinase-2 (Tie2). Ang-2 has a destabilizing effect on the endothelium,
35
 whereas 
ang-1 improves endothelial barrier function, inhibits vascular leak, and acts on adhesion 
molecules and cell junctions to exert anti-inflammatory effects.
36,37
 Ang-2 primes the 
endothelium to respond to proinflammatory (TNF and IL-1) and angiogenic (vascular 
endothelial growth factor [VEGF]) stimuli, which propagates further endothelial 
activation and increases vascular permeability.
38
 The soluble form of the receptor for 
VEGF, fms-like tyrosine kinase (sFLT)–1, competes with the membrane-bound form of 
the receptor to bind VEGF.  
 8 
In summary, the host response to sepsis is a complex interplay between inflammatory, 
anti-inflammatory, and microcirculatory alterations. This project focuses on 11 
biomarkers involved in the endothelial response to sepsis. The endothelium is a key 
regulator in maintaining vascular homeostasis and endothelial activation is thought to 
contribute to the vascular leak, tissue hypoxia, and multi-organ failure in severe sepsis. 
The mechanisms leading to a pathogenic endothelial response are not completely 
understood but likely involve prolonged, systemic endothelial activation leading to 
release of proinflammatory and cytotoxic mediators and growth factors, resulting in 
vessel instability and leakage of fluids from the vasculature.  
 
Biomarkers for prediction of sepsis mortality 
 
A recent systematic review by Pierrakos and Vincent identified 178 biomarkers in 3,370 
clinical and experimental studies evaluated for their diagnostic or prognostic value in 
patients with sepsis.
39
 The biomarkers encompassed a wide range of biologic pathways, 
including coagulation, the complement cascade, endothelial activation, inflammation, and 
apoptosis. The authors grouped the biomarkers as follows: 1) cytokine/chemokines (12 
biomarkers); 2) cell markers (14 biomarkers); 3) receptors (17 biomarkers); 4) 
coagulation (8 biomarkers); 5) vascular endothelial damage (15 biomarkers); 6) 
vasodilation (15 biomarkers); 7) organ dysfunction (17 biomarkers); 8) acute phase 
proteins (9 biomarkers); and 9) other (71 biomarkers). The majority of the biomarkers 
were assessed for their prognostic value, and none had sufficient (defined as >90%) 
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sensitivity or specificity to be clinically useful. The authors concluded that combinations 
of biomarkers should be evaluated in future studies.  
A recent systematic review by Xing et al. searched for studies evaluating 12 endothelial 
activation markers for their diagnostic or prognostic value, and identified 61 studies 
meeting their criteria.
40
 Eleven studies investigated the relationship between sICAM-1 
and mortality, only five of which found high concentrations of sICAM-1 associated with 
death.
40
 Six studies investigated the association between Ang-2 concentration and 
mortality. Four of the six studies found that elevated concentrations of Ang-2 were 
significantly associated with mortality. Other studies found that Ang-1, but not Ang-2 
concentrations predict 28-day mortality.
41
  
The association of vWF with sepsis mortality was investigated in ten studies, six of 
which found a significant relationship between elevated vWF concentration and death.
40
 
Four studies investigated the relationship between VEGF concentration and mortality, 
and its soluble receptor sFlt-1 was evaluated in one study.
40
 Two studies found no 
association between VEGF concentration and mortality,
27,42
 one study reported 
significantly higher concentrations of VEGF in survivors,
43
 and one study found 
significantly higher concentrations of VEGF in non-survivors.
44
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Epidemiology of sepsis 
Incidence and mortality 
The difficulty in clearly defining sepsis has hampered efforts to understand the 
epidemiology. The definitions developed in the Consensus Conferences differ from those 
used in the International Statistical Classification of Diseases and Related Health 
Problems (ICD) coding system for septicemia, which is defined as bacteria in the blood. 
Estimates derived from hospital discharge records from seven large states in the US in 
1995 suggested a national annual incidence of 3 cases of severe sepsis per 1,000 
population (751,000 cases per year).
45
 The current number of cases of severe sepsis in the 
US is likely over 1 million per year.
4
 The incidence of severe sepsis has been increasing 
in the US over the last 20 years, likely partially due to the growing elderly population.
46
 
Approximately 50% of patients with severe sepsis receive intensive care, and 25% die in 
the hospital.
5
 With advances in intensive care and increased awareness, the case fatality is 
decreasing for patients with severe sepsis.
11,46
  
Epidemiologic data are lacking for sepsis in developing countries; however, a recent 
systematic review and meta-analysis estimated that approximately 13.5% of adult 
patients admitted to the hospital in Africa had a bloodstream infection.
6
 In developed 
countries, the majority of patients with severe sepsis are elderly. In the US, the incidence 
of severe sepsis was over 100 times higher in those over 85 years of age versus 
children.
45
  
Although data are limited, HIV infection is thought to be an important contributor to 
sepsis incidence in developing countries.
47
 A recent systematic review of community-
 11 
acquired bloodstream infections (BSI) in hospitalized patients compared the relative risk 
of BSI in HIV infected versus uninfected patients.
48
 The investigators identified 16 
studies of BSI in adults and found that 20% of HIV infected patients had a positive blood 
culture compared to 9.2% of HIV uninfected patients. The authors concluded that HIV 
infected patients are at increased risk of bloodstream infections. The increased risk is 
thought to be due to immunosuppression; however, a study conducted in the US found no 
difference in CD4
+
 T cell counts between HIV infected patients with and without BSIs.
49
 
In contrast, other studies have reported increased incidence of BSI in HIV infected 
patients with lower CD4
+
 T cell counts.
50–52
   
 
Project Aims 
The overall goal of this project was to accurately predict the time to death for sepsis 
patients in Uganda using markers involved in the endothelial response to infection. There 
is substantial evidence from developed countries that endothelial markers measured at the 
time of hospital admission are associated with increased risk of death within 28 days. We 
hypothesized that these markers would discriminate patients who die shortly after 
admission from those who have slower clinical progression. 
We first investigated the underlying heterogeneity in sepsis. We hypothesized that 
patients presenting with severe sepsis represent a mixture of latent processes and 
subgroups of individuals that can be grouped by their “endothelial response profile”. We 
characterized the underlying processes and subgroups using latent factor analysis and 
latent profile analysis, respectively (Aim 1). We then identified biomarkers that 
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accurately predict which patients will die (Aim 2). Biomarkers and patient characteristics 
with the highest predictive accuracy were used to model the relative time to death using a 
generalized gamma model (Aim 3).  
 
Conceptual Framework 
Our conceptual framework is grounded in what is known about the function of the 
biomarkers in sepsis pathogenesis (Figure 1). These 11 markers were selected based on 
their known biologic involvement in processes related to endothelial activation in patients 
with sepsis. In our framework, the biomarkers were grouped by their hypothesized role in 
the pathogenesis of sepsis (i.e. inflammation, expression of adhesion molecules, vessel 
instability, and platelet activation). Latent factor analysis was used to explore the 
correlation structure of the biomarkers and revise the conceptual framework (Chapter 2).  
 13 
 
Figure 1. Conceptual framework 
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II. Heterogeneity in Sepsis 
Background 
Sepsis is defined as a systemic inflammatory syndrome in response to an infection, and is 
classified as severe when accompanied by evidence of hypoperfusion or acute organ 
dysfunction.
1
 This broad definition combines a wide range of pathogens and sites of 
infection into one complex syndrome with substantial heterogeneity. Despite widespread 
recognition that the biologic processes leading to death differ, most studies continue to 
group together all patients with sepsis.
8
 The underlying assumption is that the host 
response to the infectious insult is consistent across the spectrum of pathogens, affected 
organ systems, and patient comorbidities. While it is unlikely that there is one consistent 
response, it is worth evaluating the hypothesis that there are distinct patterns of host 
responses.   
Microcirculatory alterations are thought to play a large role in the host response to sepsis. 
Sepsis is characterized by microvascular leak, which manifests clinically as hypotension, 
tissue edema, hypoperfusion, and organ dysfunction.
25,26
 The endothelium is a monolayer 
of cells lining of the interior surface of blood vessels that acts as a selective barrier to 
control the passage of fluids, electrolytes, proteins and cells into and out of the 
bloodstream. During the course of an infection the endothelium becomes activated, 
meaning it is more prone to clots, there is increased transmigration of leukocytes to sites 
of infection, and the vessels become leaky.
26
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This study evaluates 11 biomarkers involved in the endothelial response to sepsis, 
including angiopoietin-1 (Ang-1) and Ang-2, soluble Tie-2 receptor (sTie-2R), vascular 
endothelial growth factor (VEGF), and fms-like tyrosine kinase-1 (sFLT-1), markers of 
inflammation (Chi3L1, IP-10, TREM-1, and ICAM), and molecules involved in 
coagulation, including von Willebrand factor (vWF) and platelet factor 4 (PF4). These 
markers were selected based on their hypothesized role in endothelial activation in 
patients with sepsis. 
To evaluate whether the endothelial response to sepsis consists of one unified biological 
process, or multiple processes, latent factor analysis (LFA) was used to analyze the 
correlation structure of the biomarkers. LFA is a multivariate statistical method for 
determining the number and nature of patterns of an observed correlation structure. In 
this study, each factor represents an underlying biological process comprised of a set of 
correlated biomarkers.  
Complex diseases such as sepsis are comprised of a heterogeneous mixture of patients 
with a spectrum of underlying pathophysiologic processes. Latent profile analysis (LPA) 
is a method to ascertain subgroups of patients conforming to a particular pattern of 
indicators out of an otherwise heterogeneous population. In LPA, subgroups of 
individuals are formed such that individuals within the subgroup have common response 
probabilities. In turn, the fitted model can be used to classify patients with different 
biomarker patterns into different subgroups. LPA provides a useful means of identifying 
subgroups of patients with homogenous biomarker patterns, thus reducing the 
heterogeneity in the study population. LPA is similar to latent class analysis, but allows 
for continuous indicators.   
 16 
 
 
Methodology 
Study population 
 
The data for this project are from the second “Promoting Resource-Limited Interventions 
for Sepsis Management in Uganda” (PRISM-U2) study.
53
 PRISM-U2 was a prospective 
study of fluid resuscitation in sepsis conducted at two hospitals in Uganda from May 
2008 to May 2009. Fluid resuscitation is considered standard care in sepsis but had not 
been evaluated in developing country settings. All patients included in this analysis were 
in the intervention cohort, in which the study team managed the clinical care of the 
patient. 
Adult patients admitted to Mulago National Referral Hospital and Masaka Regional 
Referral Hospital with suspected infection were evaluated for inclusion. In order to be 
included, patients had to meet the following criteria: 1) suspected infection as determined 
by the admitting medical officer; 2) two or more of the following: a) axillary temperature 
>37.5°C or < 35.5°C, b) heart rate >90 beats/minute, c) respiratory rate >20 
breaths/minute; 3) systolic blood pressure (SBP) ≤100 mmHg; and 4) whole blood lactate 
concentration >2.5 mmol/L or Karnofsky Performance Status (KPS) score ≤40. The KPS 
measures the patient’s ability to conduct normal activities, ranging from no specialized 
care needed (100) to dead (0).
54
 A score of 40 indicates that the patient requires 
specialized care, 20 indicates the need for active supportive treatment, and moribund 
patients are assigned a score of 10. Patients with acute cerebrovascular events or 
gastrointestinal hemorrhage, or those admitted to a non-medical ward (i.e. surgical or 
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maternity wards) were ineligible for the study. A total of 426 patients were enrolled. The 
ethics committees of the University of Virginia, Makerere University, Mulago Hospital, 
the Infectious Disease Institute, and the Uganda National Council of Science and 
Technology approved the study. Informed consent was obtained from the patient or a 
surrogate if the patient was unable to provide written consent.  
 
Data collection 
Data were collected on patient demographics and clinical characteristics, and blood was 
drawn on enrollment for laboratory testing. The patient management and data collection 
were provided by trained study personnel and used a standardized data collection 
instrument. Demographic information included patient age and sex. If the patient was 
unable to provide demographic information, the data were collected from a surrogate. 
Clinical characteristics were collected on admission, and included vital signs, use of 
highly active antiretroviral therapy (HAART), duration of illness prior to hospitalization, 
Karnofsky Performance score, and Glasgow Coma Scale. Double data entry was 
conducted for quality control using Epi Info. 
 
Laboratory Testing  
Malaria thick smears, HIV serology, and point-of-care lactate assays were conducted at 
the hospitals. Lactate was measured on whole blood using a point of care lactate assay (I-
 18 
STAT, Abbott Point of Care, Inc.). Clinical laboratories near the two hospitals conducted 
the complete blood counts, CD4
+
 T cell counts, and aerobic cultures.  
Mycobacterial blood cultures: Mycobacterial blood cultures were conducted at the Joint 
Clinical Research Center in Kampala, which participates in the World Health 
Organization External Quality Assurance program for microscopy, culture and drug 
susceptibility testing. Mycobacterium tuberculosis (MTB) bacteremia was defined as 
mycobacteria blood culture positive and confirmed as tuberculosis by polymerase chain 
reaction (PCR) or antigen test.
47
 Bactec Myco/F Lytic media vials were inoculated with 
3-5 mL of blood and incubated in the Bactec 9120 at 35°C. Positive vials were examined 
for acid-fast bacilli (AFB) and morphology consistent with MTB. AFB positive cultures 
were subcultured on selective media. PCR of the IS6110 target insertion sequence or 
detection of the MPB64 protein (Capilia TB assay,
55
 Nippon Becton Dickinson Co., Ltd, 
Tokyo, Japan) was used to confirm MTB. 
Biomarker assays: For this study, data on 11 endothelial biomarkers were analyzed: Ang-
1, Ang-2, sTie2R, VEGF, sFlt-1, sICAM-1, TREM-1, Chi3L1, vWF, PF4, and IP10. All 
biomarker assays were conducted at the University of Toronto using blood drawn at 
study enrollment. The clinical samples were centrifuged at the hospital, and serum was 
stored at -20°C. Commercial enzyme-linked immunosorbent assays were used to measure 
biomarker levels (Ang-1, Ang-2, sICAM-1, TREM-1, Chi3L1, PF4, IP-10, sFlt-1, 
sTie2R, VEGF: R&D Systems, Minneapolis, MN; vWF: antibody from Dako, 
Carpinteria, CA, standard from American Diagnostica, Stamford, CT). All assays were 
conducted in duplicate. The biomarker results were reported on a continuous scale, 
measured in either picograms or nanograms per milliliter. The upper and lower limits of 
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detection for each assay are: Ang-1 (0.039 –20.000 ng/mL); Ang-2 (0.016–8.000 ng/mL); 
sICAM (0.078–4.000 ng/mL); TREM-1 (93.8-6,000 pg/mL); Chi3L1 (31.2-2,000 
pg/mL); PF4 (15.6-1,000 pg/mL); IP-10 (31.2-2,000 pg/mL); sFlt-1 (125-8,000 pg/mL); 
sTie2R (156-10,000 pg/mL); VEGF (31.2-2,000 pg/mL); vWF (1.95–2000.00 ng/ mL). 
 
Data analysis 
The analysis set was comprised of the 426 patients enrolled in the prospective study (the 
“full sample”), excluding patients missing mortality data (5) or biomarker values (106, 
Figure 2). Ninety-three of the missing biomarker values were due to loss of a shipment of 
samples, suggesting the data were missing completely at random. The final analysis set 
included 315 patients. The biomarker variables were plotted to identify outliers and 
evaluate normality. The natural logarithms of the biomarker concentrations were used for 
all biomarkers except sTie2R and IP10, which better approximated a normal distribution 
with a square root transformation. There were no severe outliers (three times the 
interquartile range below the 25
th
 percentile or above the 75
th
 percentile) after the 
transformations. The transformed variables were standardized to have a mean of zero and 
standard deviation of one. 
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Figure 2. Patients Excluded from the Analysis 
 
Latent factor analysis: Principal components analysis (PCA) was used to parse the 
biomarkers into separate indices. We determined the number of factors using several 
criteria, including the proportion of variance explained by the factor,
56
 having an 
eigenvalue greater than one,
57
 through the use of scree plots,
58
 as well as parallel 
analysis
59
 (PA). The eigenvalue greater than one criterion was used as an upper bound for 
the number of factors to retain.
56
 In PA, 1000 datasets were simulated with the same 
number of observations and variables as the study dataset. As the generated data were 
random, any correlation in the indicators was due to sampling error. Factors 
corresponding to eigenvalues greater than the random eigenvalues obtained from the PA 
were retained. Factors corresponding to eigenvalues less than or equal to the random 
eigenvalues were considered to be due to sampling error.
56
 The iterated principal factor 
method was used to estimate the factor loadings. Correlation in the biologic processes 
was expected; therefore, a promax rotation was used.
60
 Factor rotations simplify the 
factor structure and interpretability. The rotated factor pattern matrix was used to 
interpret the meaning of the factors. The rotated factor loadings in this matrix were 
standardized regression coefficients, representing the correlation between a biomarker 
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and the factor holding other factors constant. The LFA was conducted using Stata 
(StataCorp. 2009, Stata Statistical Software: Release 11. College Station, TX).   
Latent profile analysis: A series of latent profile models was evaluated to determine the 
number of latent subgroups. Several criteria were used to determine the best fitting 
model, including the Bayesian Information Criterion (BIC),
61,62
 the log likelihood, the 
Lo-Mendel Rubin test,
63
 entropy,
64
 and clinical interpretability.
65
 Once the optimal 
number of classes was determined, subjects were assigned to the most-likely class based 
on the posterior probability of class membership. Multinomial logistic regression was 
used to investigate the demographic and clinical characteristics of the latent subgroups. 
These models provide the odds of membership in a given latent class versus a reference 
latent class, with the corresponding confidence interval. The 3-step approach was used to 
account for the measurement error in the classification of patients into their most-likely 
class.
66
 Age, sex, and the natural logarithm of the CD4+ T cell count were included in the 
models as potential confounders. M-plus v.7 (Muthén and Muthén, Los Angeles, CA) 
was used to identify the best fitting LPA model and for multinomial logistic regression 
analysis.  
 
Results 
Demographic and clinical characteristics 
The demographic and clinical characteristics of the full sample and the analysis sample 
were not substantially different (Table 2). All remaining analyses were conducted using 
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the analysis set (N=315). The median patient age was 35 years (IQR 27-40), with 
approximately equal numbers of males and females. The majority of patients had a 
primary (53%) or secondary (33%) school education, and earned less than 50,000 
Ugandan Shillings (USH) per month (53%). This currently equates to approximately $20 
US dollars per month. The median systolic blood pressure was 86 mmHg (IQR 78-90). 
The patients were predominantly HIV infected (85%), with a median CD4+ T cell count 
of 40 cells/mm
3
 (IQR 11-118). Twelve percent of the patients (N=39) had a positive 
malaria smear. 
Characteristic Full Sample 
N=426 
Analysis Set 
N=315 
Demographics   
Age in years [median (IQR)] 34 (27-40) 35 (27-40) 
Female [n (%)] 219 (51) 163 (52) 
Education [n (%)]   
None 35 (9) 26 (9) 
Primary school 231 (56) 159 (53) 
Secondary school 127 (31) 98 (33) 
More than secondary school 17 (4) 17 (6) 
Income   
<50,000 USH/mo 213 (53) 154 (53) 
50,000-99,999 USH/mo 82 (21) 51 (17) 
100,000-299,999 USH/mo 77 (19) 61 (21) 
≥300,000 USH/mo 28 (7) 26 (9) 
Clinical variables   
SBP, mmHg [median (IQR)] 85 (78-90) 86 (78-90) 
HIV infected [n (%)] 368 (87) 267 (85) 
CD4+ T count, cells/mm3 [median (IQR)] 63 (15-178) 40 (11-118) 
Table 2. Demographic and Clinical Characteristics 
IQR: interquartile range; USH: Ugandan Shillings; SBP: systolic blood pressure. 
 
 
Biomarkers 
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Male and female patients did not have substantially different biomarker concentrations 
(Figures 3a and 3b), nor did the concentrations vary with age. Patients infected with HIV 
also had similar concentrations of biomarkers to non-infected patients. Visual inspection 
of scatterplots of the biomarkers (Figure 4) suggested correlation between Ang-1 and 
PF4, and between ICAM and IP10.      
 
 
Figure 3a. Concentration of Biomarkers by Sex (Natural Logarithm 
Transformation) 
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Figure 3b. Concentration of Biomarkers by Sex (Square Root Transformation) 
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Figure 4. Scatterplot matrix of endothelial biomarkers 
Visual inspection suggests correlation between Ang-1 and PF4, and between ICAM and IP10.
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Latent Factor Analysis 
PCA parsed the data into 11 components, 4 of which had eigenvalues greater than 1 
(Table 3) suggesting that a maximum of 4 latent factors should be retained. The 4
th
 
component explained 10% of the variance in the data, which points towards retention of 4 
factors. The 4 components together explained 70% of the variance in the data. The results 
of the scree plot and parallel analysis (Figure 5) provide additional evidence for a 4-factor 
model, although the 4
th
 component is only marginally above what was observed in the 
randomly generated datasets. Based on these findings, a four-factor model was selected. 
 
Table 3. Principal components analysis 
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Figure 5. Scree Plot and Parallel Analysis 
 
 
 
Factor 1 was characterized by high factor loadings for Chi3L1 (0.68), TREM1 (0.61), and 
sFlt-1 (0.50), and was interpreted as an inflammatory process (Table 4). Ang1 (0.81), PF4 
(0.93), and VEGF (0.63) loaded on factor 2, which was interpreted as vessel stabilization. 
Factor 3 was characterized by high loadings of IP-10 (0.48), vWF (0.62), and ICAM1 
(0.66), and was interpreted as leukocyte recruitment. Lastly, high loadings of Ang2 (0.51) 
and sTie-2R (0.81) characterized factor 4, interpreted as endothelial vessel instability. 
Factors 1 (inflammation) and 3 (leukocyte recruitment) were correlated (0.38). These 
results were used to modify the conceptual framework (Figure 6).  
The uniqueness of most biomarkers was low, indicating that the variance in the 
biomarkers was well explained by the four factors (Table 4). In particular, the high factor 
loadings of all three biomarkers comprising factor 2 (vessel stabilization) suggests that 
this factor was a strong predictor of Ang-1, PF4, and VEGF. Two of the biomarkers had 
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uniqueness values greater than 0.6, sFlt-1 and vWF, suggesting that there was residual 
variability in these biomarkers. Factor 4 (vessel instability) was identified by only two 
biomarkers, and is therefore at risk for misinterpretation. In other words, “vessel 
instability” may not be the correct interpretation of this factor 
 
Biomarker Factor 1 Factor 2 Factor 3 Factor 4 Uniqueness 
Ang1 -0.0257 0.8061 -0.0120 0.1859 0.3070 
Ang2 0.4548 -0.0958 -0.1203 0.5088 0.4739 
sTie2r -0.0488 0.0326 0.0950 0.8099 0.3252 
Chi3L1 0.6819 0.0603 0.1063 -0.0285 0.4862 
Ip10 0.3127 -0.1107 0.4830 -0.0653 0.5215 
vWF -0.0931 0.1015 0.6180 0.1059 0.6427 
Pf4 -0.0985 0.9275 0.0772 -0.0925 0.1365 
Trem1 0.6129 -0.0303 0.1176 0.0227 0.5415 
Icam 0.2247 0.0425 0.6611 0.0411 0.3993 
sFlt 0.4979 -0.1312 0.1539 -0.0703 0.6408 
VEGF 0.3332 0.6262 -0.0964 -0.0950 0.5299 
Table 4. Rotated Factor Pattern (Promax Rotation) 
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Figure 6. Revised Conceptual Framework 
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Latent Profile Analysis 
Several fit-statistics were evaluated to determine the number of classes (Table 5). The 
four class model had slightly lower log likelihoods, AIC, and BIC statistics. However, the 
Lo-Mendel Rubin test indicated there was no improvement in fit for a four-class versus a 
three-class model. Furthermore, the entropy of the three-class model was higher, 
suggesting higher classification certainty. Based on these results, a three-class model was 
selected. 
 
 
  
Log Likelihood AIC BIC Lo-Mendel 
Rubin 
Entropy 
1 -4911.1 9866.2 9948.8 - - 
2 -4675.5 9440.9 9609.8 <0.001 0.778 
3 -4540.7 9217.5 9472.7 0.0148 0.859 
4 -4473.7 9129.4 9470.9 0.5827 0.827 
Table 5. Fit Statistics for Latent Profile Models with 1-4 Classes 
 
The three endothelial response profiles were interpreted as quiescent, endothelial 
dysfunction, and endothelial repair. Patients in the quiescent group had biomarker 
concentrations that were below average for all 11 biomarkers (Table 6 and Figure 7). The 
biomarkers identified through the factor analysis as belonging to the vessel stabilization 
process (Ang1, PF4, and VEGF) were particularly low in the quiescent group. The group 
of patients with endothelial dysfunction was characterized by elevated concentrations of 
all biomarkers except for those involved in the vessel stabilization process. Conversely, 
the endothelial repair profile consisted of elevated concentrations of vessel stabilization 
markers and low concentrations of the other biomarkers. The quiescent group was the 
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most prevalent, comprising 39% of the patients (N=124). Thirty-four percent of the 
patients had a biomarker profile consistent with endothelial repair (N=107), and 27% 
with endothelial dysfunction (N=84).  
 
Biomarker Quiescent 
Endothelial 
Dysfunction 
Endothelial 
Repair 
Ang 1 -0.576 -0.249 0.867 
Ang 2 -0.230 0.594 -0.199 
sTie2r -0.199 0.396 -0.080 
Chi3L1 -0.339 0.755 -0.199 
ip10 -0.210 0.944 -0.499 
vWF -0.083 0.427 -0.239 
Pf4 -0.488 -0.529 0.985 
Trem1 -0.291 0.772 -0.268 
ICAM -0.243 0.753 -0.310 
sFlt -0.338 1.085 -0.460 
VEGF -0.650 0.020 0.741 
Table 6. Standardized Mean Concentrations by Latent Profile 
 
 
 
Figure 7. Heat map of Standardized Mean Biomarker Concentrations 
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The three groups were similar in their demographic characteristics (Table 7). The 
endothelial dysfunction group had a slightly lower percentage of females, but the 
difference was not statistically significant. The percentage of patients infected with HIV 
was slightly higher in the endothelial dysfunction group (91%) than in the quiescent 
(82%) and endothelial repair (83%) groups. 
 
Characteristic 
Quiescent 
(N=122) 
Endothelial 
Dysfunction 
(N=86) 
Endothelial 
Repair 
(N=107) 
Age in years [median (IQR)] 35 (27-40) 32 (27-38) 34 (29-43) 
Female [n (%)] 71 (58) 38 (44) 54 (50) 
Education    
None 6 (5) 7 (8) 13 (13) 
Primary school 68 (60) 45 (54) 46 (45) 
Secondary school 38 (33) 25 (30) 35 (34) 
More than secondary school 2 (2) 7 (8) 8 (8) 
Income    
<50,000 USH/mo 53 (48) 45 (56) 56 (55) 
50,000-99,999 USH/mo 22 (20) 16 (20) 13 (13) 
100,000-299,999 USH/mo 26 (24) 14 (17) 21 (21) 
≥300,000 USH/mo 9 (8) 6 (8) 11 (11) 
Clinical variables    
SBP, mmHg [median (IQR)] 86 (80-90) 84 (76-92) 88 (80-90) 
HIV infected [n (%)] 100 (82) 78 (91) 89 (83) 
CD4+ T count, cells/mm3 [median (IQR)] 52 (11-192) 44 (8-119) 93 (16-241) 
Table 7. Demographic Characteristics by Latent Profile 
IQR: interquartile range; USH: Ugandan Shillings; SBP: systolic blood pressure. 
 
The endothelial response profiles corresponded to differences in other frequently used 
clinical laboratory measures of patient status, including CD4+ T cell counts, white blood 
cell (WBC) counts, platelet counts, and hemoglobin concentration (Table 8). The risk of 
endothelial dysfunction compared to quiescence nearly doubled with every 1 unit 
increase in log transformed WBC count (RR=1.83, 95%CI: 1.03, 3.24), and decreased 
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with increasing CD4+ T cell counts (RR=0.76, 95%CI: 0.59, 0.96), hemoglobin 
(RR=0.87, 95%CI: 0.75, 1.02), and platelet counts (RR=0.99, 95%CI: 0.99, 0.99), 
controlling for age and sex. All three groups differed from each other in their hemoglobin 
concentrations and platelet counts, with decreased risk of endothelial dysfunction with 
increasing hemoglobin and platelet counts.     
 
Characteristic Endothelial 
Dysfunction 
(vs. Quiescent) 
 Endothelial Repair 
(vs. Quiescent) 
Endothelial 
Dysfunction  
(vs. Repair) 
Age in years  0.99 (0.94, 1.04) 1.00 (0.96, 1.03) 0.99 (0.93, 1.05) 
Female  0.49 (0.23, 1.04) 0.68 (0.32, 1.26) 0.77 (0.31, 1.89) 
Ln CD4+ T cells 0.76 (0.59, 0.96)* 0.90 (0.72, 1.11) 0.84 (0.67, 1.06) 
Ln WBC 1.83 (1.03, 3.24)* 1.38 (0.83, 2.30) 1.32 (0.63, 2.80) 
Hemoglobin 0.87 (0.75, 1.02)* 1.19 (1.02, 1.38)* 0.73 (0.59, 0.91)* 
Sqrt Platelets 0.99 (0.99, 0.99)* 1.01 (1.00, 1.01)* 0.99 (0.98, 0.99)* 
Table 8. Odds Ratios for Class Membership 
 
Mycobacterium tuberculosis infection was significantly associated with the endothelial 
dysfunction subgroup. The odds of endothelial dysfunction versus endothelial repair was 
2.7 times higher for patients with Mycobacterium tuberculosis bacteremia (95% CI=1.16, 
6.33), controlling for age, sex and CD4+ T cell count. Similarly, the odds of endothelial 
dysfunction versus quiescence was 2.5 times higher (95% CI=1.16, 5.39), controlling for 
age, sex and CD4+ T cell count.    
Every 1 unit increase in log-transformed PCT increased the odds of endothelial 
dysfunction versus endothelial repair by 2.8 times (95% CI=1.98, 4.03), controlling for 
age, sex and CD4+ T cell count. Every 1 unit increase in log-transformed PCT increased 
 34 
the odds of endothelial dysfunction versus quiescence by 3 times (95% CI=2.07, 4.50), 
controlling for age, sex and CD4+ T cell count.  
 
Discussion 
Sepsis is widely recognized as a complex, heterogeneous syndrome.
8
 This study aimed to 
rigorously evaluate a panel of biomarkers involved in the endothelial response to sepsis 
in order to better characterize the nature of the underlying heterogeneity. Analysis of the 
correlation structure of the biomarkers identified patterns suggesting that the biomarkers 
are involved in four distinct processes, interpreted as “inflammation”, “vessel 
stabilization”, “leukocyte recruitment”, and “vessel instability”.  
 
Biological processes 
The inflammation factor consisted of the biomarkers Chi3L1, TREM1, and sFlt-1. All 
three are involved in the monocyte response to infection. TREM1 and sFlt-1 are receptors 
expressed on monocytes, which lead to secretion of proinflammatory mediators when 
activated. TREM1 amplifies the inflammatory response in extracellular bacterial and 
fungal infections.
67
 Once activated, the cellular receptors are shed from the cell surface. 
Activated macrophages and neutrophils secrete Chi3L1, which has a proinflammatory 
effect. The biologic activity of Chi3L1 is not completely understood, but it is associated 
with inflammatory conditions such as rheumatoid arthritis and has been shown to 
upregulate VEGF expression and promote angiogenesis.
68
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Ang-1, PF4, and VEGF loaded on factor 2, which was interpreted as vessel stabilization. 
All three molecules are involved in angiogenesis, the formation of blood vessels from 
pre-existing blood vessels. Gavard et al. investigated the biologic relationship between 
Ang-1 and VEGF, and found that Ang-1 prevents VEGF from disrupting endothelial cell 
to cell contacts, thus stabilizing blood vessels and preventing vascular leak.
69
 PF4 has 
several biological functions, and inhibits the angiogenic effects of VEGF.
70
 Furthermore, 
a murine model of sepsis-induced acute lung injury demonstrated that disruption of PF4 
prevented lung edema and tissue damage.
71
 Given the biologic functions of the 
constituent biomarkers, this factor likely plays a protective role in sepsis pathogenesis.      
Factor 3 was characterized by high loadings of IP-10 (0.48), vWF (0.62), and ICAM1 
(0.66), and was interpreted as leukocyte recruitment. Transendothelial migration of 
leukocytes to sites of inflammation occurs in a multistep process involving rolling across 
the endothelium, integrin activation to stop leukocyte motility, and adhesion and 
transmigration of the cell across the endothelium. The processes of leukocyte rolling and 
leukocyte adhesion have both been shown to be dependent on the presence of vWF in 
inflamed veins.
72
 IP-10 is a chemokine that is produced at high levels by activated 
endothelial cells, and is involved in leukocyte transmigration.
73
 The firm adhesion of 
leukocytes to the endothelial cell is mediated by ICAM-1, an adhesion molecule 
expressed on endothelial cells.    
Lastly, high loadings of Ang2 (0.51) and sTie-2R (0.81) characterized factor 4, 
interpreted as endothelial vessel instability. Ang-2 competes with Ang-1 for their 
receptor, sTie-2R. When bound to sTie-2R, Ang-2 primes the endothelium to respond to 
proinflammatory and angiogenic (VEGF) stimuli, propagating further endothelial 
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activation and destabilizing the endothelial vasculature.
38
 Endothelial barrier integrity is 
tightly regulated and is altered during sepsis. Ang-2 and Tie-2R signaling plays a critical 
role in disrupting the endothelial barrier resulting in net extravasation of fluid from the 
vascular space into the tissues.
35
  
The four-factor model explained the variability in most of the biomarkers. Of the 11 
biomarkers, 2 had uniqueness values greater than 0.6, sFlt-1 and vWF, suggesting that 
there was residual variability in these biomarkers not explained by the 4 factors. It is 
possible that these biomarkers are involved in other relevant processes not captured in 
this study. Factor 4 (vessel instability) was identified by only two biomarkers, and is 
therefore at risk for misinterpretation. However, there has been extensive study on the 
relationship between Ang-2 and its receptor, sTie-2R, supporting the interpretation of this 
factor as vessel instability.   
 
Latent subgroups 
Three subgroups of patients with severe sepsis were identified with distinct host 
endothelial response profiles, interpreted as: endothelial dysfunction (27%), endothelial 
repair (34%), and quiescent (39%). The group with endothelial dysfunction was 
characterized by elevated concentrations of all biomarkers except for those involved in 
the angiogenic process (Ang1, PF4, and VEGF). Conversely, the endothelial repair 
profile consisted of elevated concentrations of angiogenic markers and low 
concentrations of the other biomarkers. Patients in the quiescent group had biomarker 
concentrations that were below average for all 11 biomarkers. The cytokine responses for 
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patients with severe sepsis were summarized in a recent review to typically follow one of 
three patterns: 1) rapid production of both proinflammatory and anti-inflammatory 
cytokines, 2) predominance of anti-inflammatory cytokines, or 3) globally depressed 
production of cytokines.
12
 It would be interesting to investigate whether the three 
cytokine patterns described in the review correspond to the endothelial response profiles 
identified in this study.  
The patients in the three subgroups were similar in their demographic characteristics, yet 
there were significant differences in their clinical laboratory values. This finding suggests 
that there is clinical relevance to the three endothelial response profiles. An endothelial 
dysfunction profile was associated with low CD4+ T cell counts, low platelet counts, low 
hemoglobin concentrations, and elevated WBC counts, controlling for age and sex. The 
risk of being in the endothelial repair group increased with increasing hemoglobin 
concentrations and platelet counts.  
Patients infected with MTB were at approximately 2.5 times higher risk of endothelial 
dysfunction compared to patients without MTB bacteremia, controlling for age, sex, and 
CD4+ T cell count. This finding supports the theory that different pathogens may elicit 
different endothelial responses. However, only 38% of patients with endothelial 
dysfunction were infected with MTB, suggesting that the endothelial response is not 
completely pathogen specific. Few studies have specifically investigated endothelial 
activation in patients with MTB. Ragno et al. examined changes in gene expression in 
macrophages infected with MTB and found upregulation of genes encoding VEGF and 
its receptor sFlt-1, among other genes thought to be involved in immunoregulation.
74
 
VEGF 
75,76
 and ICAM-1
77
 concentrations were also found to be higher in patients with 
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active pulmonary tuberculosis than in patients with inactive pulmonary tuberculosis. 
Patients with active pulmonary tuberculosis had significantly higher concentrations of 
PF4 than control patients,
78,79
 and one study found PF4 levels correlated with the extent 
of pulmonary lesions on chest radiography.
79
 In a study of patients with pleural effusions, 
vWF levels were significantly higher in patients with tuberculosis than the other 
etiologies.
80
 Among patients with pulmonary MTB, TREM-1 concentration ≥128 pg/mL 
was associated with 6-month mortality and the presence of disseminated tuberculosis,
81
 
but does not differentiate tuberculosis from pneumonia caused by extracellular bacteria.
82
 
Although the evidence for the contribution of endothelial dysfunction to MTB 
pathogenesis is limited, further investigation may be warranted, particularly as most 
studies focused on pulmonary tuberculosis.    
The decisions regarding both the number of factors as well as the number of subgroups 
were guided by several well-established criteria but are ultimately somewhat arbitrary. In 
the LFA, we chose a four-factor model, but an argument could also be made for a three-
factor solution. While selecting too few or too many factors both have consequences for 
the interpretation of the data, specifying too many factors would likely lead to inclusion 
of minor factors, and was considered more acceptable than potentially losing important 
information by specifying too few factors. Furthermore, the fourth factor was comprised 
of Ang-2 and its receptor sTie-2R, which is conceptually consistent with the known 
biology of the two molecules. In the LPA, the log-likelihood and BIC were marginally 
better for the four-class solution. However, simulation studies suggest that the Lo-Mendel 
Rubin test is more accurate for selecting the correct number of classes. In addition, the 
entropy statistic suggested that the three-class solution formed more distinct groups. 
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Sepsis encompasses a wide range of pathogens and sites of infection within a single 
complex syndrome with substantial heterogeneity. We reasoned that one consistent host 
response is unlikely and sought to evaluate the hypothesis that there are distinct patterns 
of host responses.  We evaluated a panel of biomarkers involved in the endothelial 
response to sepsis to better characterize the nature of the underlying heterogeneity. 
Analysis of the correlation structure of the biomarkers identified patterns suggesting that 
the biomarkers are involved in four distinct processes, interpreted as “inflammation”, 
“vessel stabilization”, “leukocyte recruitment”, and “vessel instability”. These processes 
may represent therapeutic targets. Three subgroups of patients with severe sepsis were 
identified with distinct host endothelial response profiles, interpreted as: endothelial 
dysfunction, endothelial repair, and quiescent. The patients in the three subgroups were 
similar in their demographic characteristics yet had significant differences in their clinical 
laboratory values. The presence of three endothelial response profiles supports the 
hypothesis that there are distinct patterns of endothelial responses, which may have 
important implications for patient care. Further research is needed to establish the clinical 
relevance of the endothelial response profiles and to determine whether similar subgroups 
are found in populations with different pathogens, host genetics, and patient 
comorbidities.  
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III. Predicting who dies  
Background 
Sepsis is a complex syndrome resulting in disturbances in a myriad of biologic systems. 
A recent systematic review of sepsis identified 178 biomarkers in 3,370 clinical and 
experimental studies.
39
 The biomarkers encompassed a wide range of biologic pathways, 
including coagulation, the complement cascade, endothelial activation, inflammation, and 
apoptosis. The authors concluded that none of the biomarkers with published accuracy 
measures had adequate sensitivity or specificity for use in clinical practice, but that 
combinations of biomarkers should be evaluated in future studies. Lactate, procalcitonin 
(PCT) and C-reactive protein (CRP) have been studied most extensively in sepsis 
prognosis, and have been employed in some routine clinical practices.
39,83,84
 The 
Surviving Sepsis treatment guidelines strongly recommend that patients with hypotension 
or serum lactate levels >4 mmol/L receive immediate fluid resuscitation.
85
 However, 
accurate lactate testing is challenging, as levels continue to rise in the collected sample, 
resulting in falsely elevated levels unless testing can be conducted immediately.
86
 Point 
of care lactate tests have been developed but the area under the curve was 0.72 for 
predicting mortality in a recent study.
86
 High levels of procalcitonin were found to 
identify septic patients at risk of developing severe sepsis, but were not sensitive enough 
for clinical decision making.
87
 
A recent systematic review by Xing et al. focused specifically on biomarkers of 
endothelial dysfunction for the diagnosis, prognosis, or risk-stratification of patients with 
sepsis.
40
 The authors searched MEDLINE for the keyword ‘sepsis’ together with names 
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of relevant biomarkers (Ang-1 and -2, sTie2R, sVEGF, sFlt-1, sICAM-1, sVCAM-1, sE-
selectin, endothelin-1, endocan, vWF, and ADAMTS13), and identified 1,243 studies, 61 
of which met pre-specified criteria. Six studies investigated the association between Ang-
2 concentration and mortality, four of which found that Ang-2 concentration was 
significantly associated with mortality. However, few of these studies provided 
discrimination or calibration metrics. Riccuito et al. enrolled 70 patients upon admission 
to the ICU and assessed the predictive accuracy of Ang-1 and Ang-2 concentrations.
41
 
Ang-1, but not Ang-2 concentrations were found to predict 28-day mortality, adjusting 
for age and multi-organ dysfunction score. The authors developed a score incorporating 
Ang-1, Ang-2, ICAM-1, vWF, and E-selectin that accurately discriminated survivors 
from those who died by day 28 with an area under the receiver operating characteristic 
(ROC) curve (AUC) of 0.80 (95%CI: 0.69-0.90). However, the score used empirically 
derived cut-offs for the biomarkers and the accuracy metrics were calculated based on the 
same data used to generate the score. Thus, the predictive accuracy of the score in other 
populations will likely be lower than described by the authors.  
The systematic review by Xing et al. identified 11 studies investigating the relationship 
between sICAM-1 and mortality. Only five of the studies found that high concentrations 
of sICAM-1 was significantly associated with death.
40
 Two of the studies reported 
discrimination metrics, although one study had only fourteen patients.
88
 The remaining 
study reported that sICAM-1 predicted mortality in the emergency department with an 
AUC of 0.72 (95%CI: 0.57 to 0.87).
89
 Ten studies evaluated vWF for association with 
sepsis mortality, six of which found a significant relationship between vWF concentration 
and death.
40
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VEGF was evaluated for its prognostic ability in four studies, and its soluble receptor 
sFlt-1 was evaluated in one study.
40
 The results were conflicting for VEGF; two studies 
found no association between VEGF concentration and mortality,
27,42
 one study reported 
significantly higher concentrations of VEGF in survivors,
43
 and one study found 
significantly higher concentrations of VEGF in non-survivors.
44
 Yang et. al investigated 
both VEGF and sFlt-1 in patients with pneumonia-related septic shock and found that the 
patients who died of septic shock had significantly higher concentrations of sFlt-1 (659 
pg/ml) than patients with septic shock who survived (221 pg/ml).
27
 The concentration of 
VEGF was not associated with mortality.  
This study builds on the results obtained in Aim 1, to determine whether an endothelial 
dysfunction profile predicts 28-day mortality, and to evaluate other candidate predictors.  
 
Methods 
Study population 
 
This aim utilizes the same study population as Aim 1. Briefly, data for this project are 
from a prospective study of fluid resuscitation in patients with severe sepsis conducted at 
two hospitals in Uganda from May 2008 to May 2009. Adult patients had to meet the 
following criteria: 1) suspected infection as determined by the admitting medical officer; 
2) two or more of the following: a) axillary temperature >37.5°C or < 35.5°C, b) heart 
rate >90 beats/minute, c) respiratory rate >20 breaths/minute; 3) systolic blood pressure 
(SBP) ≤100 mmHg; and 4) whole blood lactate concentration >2.5 mmol/L or Karnofsky 
Performance Status (KPS) score ≤40. Patients were excluded for acute cerebrovascular 
 43 
events or gastrointestinal hemorrhage, or for admission to a non-medical ward (i.e. 
surgical or maternity wards). A total of 426 patients were enrolled and 315 patients were 
included in the analysis after excluding those with missing outcome measures or 
biomarker measurements. The ethics committees of the University of Virginia, Makerere 
University, Mulago Hospital, the Infectious Disease Institute, and the Uganda National 
Council of Science and Technology approved the study. Informed consent was obtained 
from the patient or a surrogate if the patient was unable to provide written consent.  
 
Data collection 
Data were collected on patient demographics and clinical characteristics, and blood was 
drawn on enrollment for laboratory testing. Demographic information included patient 
age in years, sex, education and income. Clinical characteristics were collected on 
admission, and included vital signs and Karnofsky Performance score.  
 
Laboratory Testing  
As described in Aim 1, HIV serology, and point-of-care lactate assays were conducted at 
the hospitals. Lactate was measured on whole blood using a point of care lactate assay (I-
STAT, Abbott Point of Care, Inc.). Clinical laboratories near the two hospitals conducted 
the CD4
+
 T cell counts and aerobic cultures. The endothelial biomarkers described in 
Aim 1 were used for Aim 2: Ang-1, Ang-2, sTie2R, VEGF, sFlt-1, sICAM-1, TREM-1, 
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Chi3L1, vWF, PF4, and IP10. All biomarker assays were conducted at the University of 
Toronto using blood drawn at study enrollment.  
 
Data analysis 
Two outcomes were considered, 28-day mortality and 3-day mortality. The 3-day 
mortality outcome was used to predict which patients were at risk of imminent death. 
Time was measured in days from hospital admission. 
Candidate markers included the following: endothelial biomarkers (Ang-1, Ang-2, 
sTie2R, VEGF, sFlt-1, sICAM-1, TREM-1, Chi3L1, vWF, PF4, and IP10), CD4+ T cell 
count, lactate, procalcitonin, C-reactive protein (CRP), WBC count, platelet count, and 
hemoglobin concentration. The patient’s endothelial response profile (from Aim 1) and 
Karnofsky score were also considered.  
 
Statistical Methods 
The data were divided into a derivation set and a validation set, with the derivation set 
comprised of a random sample of two thirds of the data. The candidate predictors were 
dichotomized for ease of interpretation in the predictive models. The endothelial 
biomarkers, WBC count, platelet count, and hemoglobin levels were divided into 
quintiles and dichotomized into above or below the fifth quintile. A low CD4+ T cell 
count was defined as below 50 cells/mm
3
. The Karnofsky score was defined as 20 or less.  
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The discriminative value of the candidate predictors for predicting which patients would 
die was assessed using logistic regression. The predictors were removed from the full 
model using backwards selection based on the univariate AUCs. If the AUC of the model 
decreased by more than 0.025 when a candidate predictor was removed, the predictor was 
put back in the model.  
The ability of the model to discriminate those who died from those who survived was 
quantified by calculating the AUC. The calibration of the model was assessed using the 
Hosmer-Lemeshow 
2
 statistic. Calibration metrics measure how closely the predicted 
outcomes agree with the actual outcomes. The predicted versus actual event rates were 
compared for each decile of predicted risk in both the derivation and validation sets.  
 
Results 
The demographic characteristics of patients in the derivation and validation sets were 
similar, except that the validation set had significantly fewer females (p=0.04). The 
percentage of patients infected with HIV was similar in the derivation (84%) and 
validation (86%) sets. In both the derivation and validation sets, approximately 38% of 
the patients died. The demographic characteristics of patients who died were similar to 
the patients who survived in both the derivation and validation sets (Table 9).  
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Characteristic 
Derivation Set Validation Set 
Died 
N = 75 
Survived 
N = 120 
Died 
N = 37 
Survived 
N = 60 
Demographics     
Age in years [median (IQR)] 34 (26-40) 34 (28-42) 35 (31-40) 34 (27-40) 
Female [n (%)] 40 (53) 70 (58) 13 (35) 26 (43) 
Education [n (%)]     
None 5 (7) 14 (12) 2 (5) 3 (5) 
Primary school 38 (51) 57 (50) 19 (54) 33 (59) 
Secondary school 27 (36) 37 (32) 10 (29) 18 (32) 
More than secondary school 4 (5) 6 (5) 4 (11) 2 (4) 
Income     
<50,000 USH/mo 38 (55) 55 (50) 15 (45) 32 (56) 
50,000-99,999 USH/mo 10 (14) 24 (22) 5 (16) 10 (18) 
100,000-299,999 USH/mo 17 (25) 22 (20) 7 (21) 9 (16) 
≥300,000 USH/mo 4 (6) 10 (9) 6 (18) 6 (11) 
Clinical variables     
SBP, mmHg [median (IQR)] 80 (70-90) 90 (80-90) 80 (70-90) 86 (80-90) 
HIV infected [n (%)] 69 (92) 98 (82) 37 (100) 46 (77) 
CD4+ T count, cells/mm3 
[median (IQR)] 
24 (7-101) 86 (24-205) 21 (6-100) 82 (12-206) 
Table 9. Demographic characteristics by 28-day mortality in the derivation and 
validation sets 
IQR: interquartile range; USH: Ugandan Shillings; SBP: systolic blood pressure. 
 
 
Mortality prediction (derivation set) 
The univariate AUC and odds ratio for predicting 28-day mortality are shown in Table 
10. Selection of predictors with the highest discriminative value resulted in a reduced 
model consisting of the endothelial dysfunction profile, CD4+ T cell count less than 50, 
and Karnofsky score less than or equal to 20. The biomarker sFlt-1 did not contribute to 
the prediction of which patients would die, however, it predicted the time of death 
(described in Aim 3) and was therefore retained in the final model.  
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Predictor AUC OR p-value 
Endothelial dysfunction 0.61 2.83 (1.50, 5.34) 0.001 
Ang 1 0.48 0.72 (0.34, 1.54) 0.404 
Ang 2 0.53 1.47 (0.71, 3.02) 0.300 
sTie2r 0.50  0.95 (0.46, 1.95) 0.889 
Chi3L1 0.56 2.06 (1.01, 4.22) 0.048 
ip10 0.60 3.29 (1.59, 6.81) 0.001 
vWF 0.57 2.35 (1.16, 4.76) 0.018 
Pf4 0.48 0.76 (0.35, 1.69) 0.507 
Trem1 0.55 2.05 (0.97, 4.33) 0.059 
ICAM 0.59 2.88 (1.40, 5.90) 0.004 
sFlt-1 0.53 1.50 (0.73, 3.02) 0.271 
VEGF 0.46 0.56 (0.25, 1.23) 0.148 
CD4<50 0.64 3.07 (1.69, 5.60) <0.001 
Lactate 0.54 1.68 (0.82, 3.45) 0.160 
Hemoglobin 0.56 2.20 (1.07, 4.55) 0.033 
Karnofsky score 0.57 8.18 (2.25, 29.78) 0.001 
CRP 0.47 0.65 (0.29, 1.45) 0.293 
PCT 0.49 0.90 (0.44, 1.84) 0.781 
WBC 0.46 0.56 (0.25, 1.23) 0.148 
Platelet 0.54 1.53 (0.77, 3.04) 0.221 
Table 10. Univariate discriminative values for 28-day mortality 
 
 
The odds of death within 28 days were approximately 3 times higher for patients with an 
endothelial dysfunction profile (95%CI: 1.36, 7.52), as well as for patients with a CD4+ T 
cell count less than 50 cells/mm
3
 (95%CI: 1.51, 5.38, Table 11). Patients with a 
Karnofsky Score of 20 or less had 6 times the odds of death (95%CI: 1.58, 23.01).  
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Predictor OR p-value 
Endothelial dysfunction 3.2 (1.39, 7.52) 0.008 
CD4<50 2.85 (1.51, 5.38) 0.001 
Karnofsky score 6.04 (1.58, 23.01) 0.008 
sFlt-1 0.66 (0.25, 1.73) 0.396 
Table 11. Final model for predicting 28-day mortality 
 
Model accuracy 
The AUC of the final model for predicting 28-day mortality was 0.73 in the derivation set 
and 0.77 in the validation set (Figure 8). The model discrimination was improved when 
predicting 3-day mortality (AUC= 0.79 in the derivation set, and 0.74 in the validation 
set). The Hosmer-Lemeshow 
2
 statistic was 1.45 (p=0.92) in the validation set, 
indicating that the model fit the data well.   
 
Figure 8. ROC curve for 28-day mortality, validation set 
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Discussion 
Sepsis remains a leading cause of death in both developing and developed countries. 
Although accurate estimates are lacking, the burden of sepsis may be greatest in 
developing countries.
90
 A recent systematic review and meta-analysis estimated that 
approximately 13.5% of adult patients admitted to the hospital in Africa had a 
bloodstream infection.
6
 Methods to accurately predict prognosis are needed to guide 
clinical decision-making and avoid delays in treatment.   
Nearly 200 biomarkers have been evaluated for their diagnostic or prognostic value, yet 
no individual or combination of biomarkers has proven to be sufficiently accurate for 
clinical use.
39
 In this study, endothelial dysfunction, CD4+ T cell count less than 50 
cells/mm
3
, and Karnofsky score of 20 or less predicted 28-day mortality. Endothelial 
dysfunction was associated with 28-day mortality, but did not accurately discriminate 
patients who would die within 28 days on its own. There are several likely reasons for the 
poor discriminative value. First, 28 days may not be an appropriate end point for 
endothelial biomarkers measured at hospital admission. This approach groups together 
patients who died on day 2 together with those who died on day 25, for example, and 
assumes that the biological processes leading to death are similar and measurable at 
baseline. This assumption is likely false, especially considering that events occurring 
over the course of the hospitalization, such as nosocomial infections, may have a 
dramatic impact on the clinical outcome. Shortening the timeframe for the prediction or 
repeat measurement of the biomarkers would likely improve the discriminative value. 
Thus, we also evaluated the discriminative value of the model for predicting a three-day 
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mortality outcome and found that the ability of the biomarkers to accurately predict 
mortality was improved.  
The discriminative value of the individual endothelial biomarkers for predicting 28-day 
mortality in this study was similar to results obtained in developed countries. Riccuito et 
al. enrolled 70 patients with severe sepsis upon admission to the ICU in 3 hospitals in 
Canada and found that Ang-1 concentrations ≤5.5 ng/mL predicted 28-day mortality with 
an AUC of 0.62,
41
 compared to the AUC of 0.48 observed in this study. The investigators 
also measured Ang-2, vWF, and ICAM-1, but did not report the individual discriminative 
values of these biomarkers. Shapiro et al. investigated sFlt-1 and ICAM-1 for their ability 
to predict in-hospital mortality among 221 patients presenting to the emergency 
department of a US academic medical center with clinical suspicion of infection.
89
 The 
study population was comprised of patients with sepsis (32%), severe sepsis (30%), 
septic shock (32%), and non-infected controls (6%). In this population, sFlt-1 predicted 
in-hospital mortality with an AUC of 0.91, and ICAM-1 predicted mortality with an AUC 
of 0.72. Valid comparisons across studies are difficult as the biomarker cut-off values and 
inclusion criteria are vastly different. Furthermore, the biomarker cut-offs are often not 
reported or are empirically derived. Nonetheless, the similarity of the results found in this 
study to those from developed countries suggests that the HIV infection status of the 
patients may not impact the discriminative value of the endothelial biomarkers. Further 
research is needed to determine the effect, if any, of immunosuppressive conditions such 
as HIV infection on the predictive value of the biomarkers.  
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Our study had several strengths. We derived the predictive model in a randomly assigned 
derivation set and evaluated the accuracy of the model in a separate set of patients (i.e. 
the validation set). This approach gives more realistic measures of predictive accuracy as 
the data used to develop the model were not used to evaluate the model. Secondly, the 
discriminative values were used to select the predictors in the final model, as opposed to 
selecting predictors based on the p-value for their association with the outcome. 
Predictors may have a significant p-value yet have low discriminative value. 
Furthermore, these findings provide information previously lacking for patients in low-
resource settings.  
Our study was limited in that the biomarkers were measured only at hospital admission. 
While ideally a prognostic test would require only one measurement, it is possible that 
changes in biomarker concentration over time would be more predictive of outcome. This 
may partially be due to the variation in the stage at which patients present to the hospital. 
Some patients may seek care earlier in the course of illness than others and some 
infections may have a fulminant clinical course. Measuring the change in a biomarker 
over time may account for these differences. However, an ideal prognostic test would be 
informative regardless of when in the course of illness the patient presents to the hospital.       
We investigated the accuracy of a novel method of profiling patients with severe sepsis 
based on their endothelial response patterns for predicting 28-day mortality. We 
identified endothelial dysfunction, CD4+ T cell count less than 50 cells/mm3, and 
Karnofsky score of 20 or less predicted 28-day mortality with an AUC of 0.77 in the 
validation set. Further research is needed to externally validate these findings in patient 
populations with different infectious etiologies. 
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IV. Predicting time of death 
 
Background 
The current treatment strategy for sepsis relies on early goal-directed therapy, including 
fluid resuscitation within the first 6 hours of recognition of sepsis and administration of 
broad-spectrum antibiotics within 1 hour of diagnosis of septic shock.
85
 Early recognition 
and treatment is considered paramount, as several studies demonstrated an increased 
mortality risk in patients receiving delayed treatment.
91,92
 In particular, studies have 
shown decreased survival with every hour delay in the time to administration of 
appropriate antibiotics.
93,94
 Aggressive hemodynamic optimization is also most effective 
when administered before the development of global tissue hypoxia.
95
 However, early 
recognition of sepsis is difficult as physiologic derangements such as hypotension may be 
absent early in the course of illness.
96
 A prognostic test that could identify which patients 
are at highest risk of clinical progression, and among those at high risk, discriminate 
patients who will die shortly after admission from those who have slower disease 
progression would provide important information for clinical decision-making. Patients at 
high risk of imminent death may be candidates for more aggressive therapy, which might 
not be justified for patients with a less fulminant clinical course. Furthermore, analysis of 
biomarkers associated with the time of death may provide insight into sepsis pathogenesis 
and may facilitate identification of risk factors for rapid decline. This study builds on the 
results obtained in Aim 2 by incorporating information on the time of death.  
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Methods 
Study population 
 
This aim uses the same study population as Aim 1 and 2. Briefly, adult patients meeting 
the following criteria were enrolled: 1) suspected infection as determined by the 
admitting medical officer; 2) two or more of the following: a) axillary temperature 
>37.5°C or < 35.5°C, b) heart rate >90 beats/minute, c) respiratory rate >20 
breaths/minute; 3) systolic blood pressure (SBP) ≤100 mmHg; and 4) whole blood lactate 
concentration >2.5 mmol/L or Karnofsky Performance Status (KPS) score ≤40. Patients 
were excluded for acute cerebrovascular events or gastrointestinal hemorrhage, or for 
admission to a non-medical ward (i.e. surgical or maternity wards).  
Data were collected on patient demographics and clinical characteristics, and blood was 
drawn on enrollment for laboratory testing. Demographic information included patient 
age in years, sex, education and income. Clinical characteristics were collected on 
admission, and included vital signs and Karnofsky Performance score. The time of death 
was measured in days after admission to the hospital. 
 
Laboratory Testing  
As described in Aim 1, HIV serology, and point-of-care lactate assays were conducted at 
the hospitals. Lactate was measured on whole blood using a point of care lactate assay (I-
STAT, Abbott Point of Care, Inc.). Clinical laboratories near the two hospitals conducted 
the CD4
+
 T cell counts, and aerobic cultures. The endothelial biomarkers described in 
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Aim 1 and 2 were used for Aim 3: Ang-1, Ang-2, sTie2R, VEGF, sFlt-1, sICAM-1, 
TREM-1, Chi3L1, vWF, PF4, and IP10.  
 
Data analysis 
A generalized gamma model was used to model the time of death among those who died. 
The generalized gamma is a parametric accelerated failure time model. The 
exponentiated model coefficients provide the time ratio for a unit change in the predictor. 
Therefore, time ratios less than one indicate a decrease in survival time and time ratios 
greater than one indicate a prolonged survival time. The predictors selected in the logistic 
regression (as described in Aim 2) were retained in the generalized gamma model, and 
the candidate predictors were evaluated for their additional contribution to the time of 
death prediction. The model fit was assessed by plotting the Cox-Snell residuals against 
the cumulative hazard function.
97
 A straight line with a slope of one indicates a good fit. 
The candidate predictors were evaluated in the derivation set.  
 
The positive and negative predictive values for the model predicting the time of death 
were assessed using a modified version of recently developed statistical methods. These 
methods model the probability of death as a function of time, given a positive (or 
negative) biomarker result. The PPV and NPV for a binary biomarker X at time t were 
defined as follows98: 
PPV x(t) = P(T ≤ t | X=1)  NPV x(t) = P(T > t | X=0) 
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The published statistical methods were modified to specifically model the time to death. 
The model specification was defined as follows: 
PPV x(t) = π* F1*(t)    NPV x(t) = π(1-F1(t)) + (1- π) 
 
Where π is the proportion of patients who die, F1(t) is the distribution of times of death, 
and * indicates that the patients were positive for the biomarker. Therefore, the PPV for 
biomarker X at time t is the proportion of patients who die before time t among those 
who tested positive for biomarker X. The NPV is interpreted as among those who tested 
negative for the biomarker, the proportion of those who do died but did so after time t, 
plus the proportion discharged from the hospital alive. The PPV and NPV of the final 
model were plotted over time.  
 
Results 
The median time to death in the derivation set was 6 days for patients with a quiescent 
endothelial response profile, 4 days for patients with an endothelial repair profile, and 2 
days for patients with endothelial dysfunction. The survival curves for the endothelial 
response profiles show that patients with endothelial dysfunction died significantly faster 
than patients in the other groups (Log-rank test p<0.0001, Figure 9). The predicted time 
to death and actual times of death were plotted for patients with and without endothelial 
dysfunction (Figure 10). The predicted times of death closely match the observed times 
of death, among those who died.  
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Figure 9. Kaplan-Meier survival curves by endothelial response profile 
 
 
 
Figure 10. Predicted Time of Death versus Actual Time of Death 
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Time of death prediction (derivation set) 
The time to death was significantly shorter for patients with an endothelial dysfunction 
profile versus the other endothelial response profiles (p=0.001, Table 12). The survival 
time for patients with endothelial dysfunction was approximately half that of patients 
with similar CD4+ T cell counts, Karnofsky scores, and sFlt-1 concentrations (relative 
time = 0.49, 95%CI: 0.32, 0.75). Interestingly, neither a CD4+ T cell count less than 50 
nor a Karnofsky Score of 20 or less were informative for the time of death among those 
who died. The survival time for patients with high concentrations of sFlt-1 was reduced 
by 43% compared to patients with lower concentrations (relative time = 0.57, 95%CI: 
0.35, 0.93). Patients with an endothelial dysfunction profile and high concentrations of 
sFlt-1 had a 72% reduction in their survival times. Thirty-three patients in the derivation 
set (16%) had both indicators of rapid decline.  
 
Predictor Estimate (95%CI) p-value 
Endothelial dysfunction -0.723 (-1.14, -0.31) 0.001 
CD4<50 0.022 (-0.36, 0.41) 0.912 
Karnofsky score 0.022 (-0.45, 0.50) 0.928 
sFlt-1 -0.557 (-1.04, -0.07) 0.024 
Constant 1.74 (1.35, 2.13) <0.001 
Sigma 0.777 0.003 
Kappa -0.226 0.501 
Table 12. Time of death 
 
 
The model fit the data well, as the hazard function closely follows the 45-degree line with 
some variation at later times (Figure 11).  
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Figure 11. Cox-Snell residual plot 
 
Positive predictive value 
The positive predictive value for patients with endothelial dysfunction, a CD4+ T cell 
count less than 50 cells/mm3, a Karnofsky score of 20 or less, and in the 5
th
 quintile of 
sFlt-1 concentration compared to patients without any of the above indicators of poor 
prognosis was plotted over time (Figure 12a). The relative positive predictive values 
(PPV) are shown in Figure 12b. These graphs show that the prediction of time of death is 
much more accurate for deaths occurring within five days of hospital admission.    
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Figure 12a. Positive predictive value over time 
 
 
Figure 12b. Relative positive predictive value over time 
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Figure 13a. Negative predictive values over time 
 
 
Figure 13b. Relative negative predictive values over time 
 
 
Discussion 
The ability to differentiate patients with severe sepsis who have a fulminant clinical 
course from patients who progress more slowly could provide important information for 
clinical decision-making. Decisions regarding the level of care required, how aggressive 
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to be with fluid resuscitation, and potentially therapeutic options could be tailored based 
on the patient’s expected clinical course. Patients with endothelial dysfunction die 
substantially sooner than patients with endothelial repair or quiescence, with a median 
time to death of 2 days versus 4 or 6 days, respectively. This difference in survival was 
demonstrated with Kaplan-Meier survival curves and the relative time to death was 
quantified using a generalized gamma parametric failure time model. The survival time 
for patients with endothelial dysfunction was approximately half that of patients with 
similar CD4+ T cell counts, Karnofsky scores, and sFlt-1 concentrations but without 
endothelial dysfunction. The biomarker sFlt-1 independently contributed to the prediction 
of the time of death, while CD4+ T cell count and Karnofsky score were not informative. 
Patients with both endothelial dysfunction and high sFlt-1 concentrations had a 72% 
reduction in their survival times compared to otherwise similar patients without the two 
indicators of poor prognosis.  
 
Clinical studies of patients with sepsis typically use 28-day mortality as the primary end 
point;
99
 few studies explicitly investigated the time to death. Macias and Nelson divided 
hospitalization days for patients with severe sepsis into three segments, day 0 to 5, day 6 
to 15, and day 16 to 28, and evaluated biomarkers and clinical variables potentially 
related to the time of death.
99
 The investigators found that the rate and cause of death 
differs over the 28-day follow-up period, with refractory shock as the major cause of 
death in the first 5 days, and respiratory failure or multi-organ dysfunction predominating 
in the later periods. Severe protein C deficiency and elevated IL-6 concentrations were 
associated with death in the early time period. These results support the hypothesis that 
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the optimal treatment strategy may differ depending on the clinical course, which 
emphasizes the need for methods to accurately predict the clinical course as early as 
possible. 
 
PPV and NPV are standard measures of predictive accuracy used with binary outcomes, 
such as 28-day mortality. However, there are no standard methods to quantify predictive 
accuracy for predicting a failure time outcome. We adapted a recently published method 
for quantifying PPV and NPV for failure time outcomes.
98
 This approach allows for 
quantification of the accuracy of a biomarker (or a set of biomarkers) for predicting the 
probability of the outcome over the course of time, as opposed to status at one point in 
time (such as at 28-days). By plotting the positive predictive value of the model as a 
function of time, we were able to illustrate that the PPV of the model is highest within the 
first 5 days of hospital admission. This result suggests that endothelial dysfunction 
combined with CD4
+
T cell count and Karnofsky score measured at baseline are most 
informative for events occurring within approximately 5 days. Future studies are needed 
to investigate the utility of serial testing and to establish the optimal timing of the repeat 
measurements. 
 
Our study had several limitations. Our scope was limited to biomarkers involved in the 
endothelial response to sepsis. While the endothelial response is an important component 
of sepsis pathogenesis, there are likely other biologic processes that influence outcome. 
Future studies incorporating a broader set of indicators may improve the accuracy of the 
prediction. Secondly, the biomarker concentrations were dichotomized into above or 
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below the fifth quintile for the study population. This approach is not optimal but was 
chosen over approaches where the cut-offs are determined with respect to the outcome of 
interest, which could lead to inflated estimates of model accuracy. Few studies of 
endothelial biomarkers for prediction of mortality report the biomarker cut-offs used, or 
the discriminative value of the biomarker.
40
 Research aiming to establish and standardize 
approaches for biomarker measurement and reporting of the results would greatly 
facilitate the analysis of future studies and allow for meaningful comparisons across 
studies. Our results were derived from patients with severe sepsis in Uganda. This patient 
population differs from most studies of patients with sepsis in that the patients are young 
(median age of 35) and predominantly HIV infected. The infectious etiologies also differ 
from those found in developed countries. Therefore, further research is needed to 
determine the generalizability of our results to other patient populations.     
 
In our study, patients with an endothelial dysfunction profile and elevated sFlt-1 
concentrations died significantly sooner than patients without those indicators, adjusting 
for CD4+ T cell count and Karnofsky score. These patients are at high risk of imminent 
death, and therefore may be candidates for more aggressive therapy. Future clinical trials 
could target this subgroup of patients, as treatment efficacy may differ depending on the 
patient’s endothelial response profile.  
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V. Summary and conclusions 
Sepsis is a leading cause of death in both developed and developing countries. Despite 
thousands of clinical and laboratory-based studies, we still lack a prognostic test with 
sufficient accuracy to be clinically useful. This project aimed to identify endothelial 
biomarkers that could accurately predict the time to death for patients with severe sepsis 
in Uganda.  
The endothelial response to an infection is complex. Using a panel of 11 biomarkers 
involved in the endothelial response, we evaluated whether the response is one-
dimensional or comprised of multiple biologic processes. The LFA results suggested four 
latent processes, interpreted as “inflammation”, “vessel stability”, “leukocyte 
recruitment”, and “vessel instability” based on the known biologic functions of the 
constituent biomarkers. Many of the biomarkers investigated have pleiotropic effects, 
depending on the context. For example, the presence of VEGF may indicate vessel 
instability, unless Ang-1 is present, in which case the destabilizing effect of VEGF is 
inhibited. Examining VEGF alone would not provide the correct interpretation. 
Analyzing the correlation structure of the biomarker panel provided a context allowing us 
to interpret the effect of the group of biomarkers.  
We next investigated whether patients with severe sepsis had one common endothelial 
response pattern, versus a patient population comprised of a mixture of latent subgroups. 
Using LPA, we identified three subgroups of patients with endothelial response patterns 
that were homogenous within the group and distinct from the other groups. The patterns 
were interpreted as “quiescent”, “endothelial dysfunction”, and “endothelial repair”. 
Patients with endothelial dysfunction were characterized by elevated concentrations of all 
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biomarkers except for those identified through the factor analysis as belonging to the 
vessel stabilization process (Ang1, PF4, and VEGF). We hypothesized that this subgroup 
would have a poor prognosis, as they had high concentrations of biomarkers associated 
with mortality and low concentrations of biomarkers involved in what was likely a 
protective process. The three endothelial response groups were similar in their 
demographic characteristics, yet their clinical laboratory values were significantly 
different. These results suggest that profiling patients with severe sepsis into subgroups 
based on their endothelial response may provide a clinically meaningful way to 
categorize patients into more homogeneous groups. These profiles may prove useful in 
future clinical trials, where homogeneous study populations are needed to detect potential 
treatment effects.  
In Chapter 3 we assessed the ability of the endothelial dysfunction profile and other 
candidate predictors to accurately predict which patients would die within 28 days of 
hospital admission. The predictors with the highest AUC were selected for inclusion in 
the final model. Endothelial dysfunction was significantly associated with 28-day 
mortality, but had poor discriminative value on its own. The final model consisted of 
endothelial dysfunction, CD4
+
 T cell count less than 50 cells/mm
3
, Karnofsky score of 20 
or less, and the 5
th
 quintile of sFlt-1 concentration. The AUC for the model for 28-day 
mortality was 0.73 in the derivation set, and 0.77 in the validation set. The discriminative 
value of this model was not accurate enough for use in the clinical management of 
patients. There are several likely reasons for the low accuracy. Our analysis was limited 
to 11 endothelial markers, 6 clinical laboratory values, and the Karnofsky score. There 
are likely other key determinants of outcome not included in our analysis. In particular, 
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the immune response is known to be an important contributor to the pathogenesis of 
sepsis. Another possible explanation of the poor prognostic value is that 28 days may not 
be an appropriate timeframe for an accurate prediction. Endothelial biomarkers measured 
at baseline may be informative for deaths occurring within five days, but later deaths are 
likely influenced by other events, such as treatment effects and nosocomial infections. 
Shortening the timeframe used to evaluate the prognostic value of endothelial biomarkers 
to 3-day or perhaps 5-day mortality would likely give more accurate predictions for 
which patients are at high risk of death. 
In Chapter 4 we investigated whether the model developed in Chapter 3 and other 
candidate predictors could accurately predict the time to death, among those who died. 
We found that patients with endothelial dysfunction died twice as fast as otherwise 
similar patients. Patients with both endothelial dysfunction and high sFlt-1 concentrations 
had a 72% reduction in their survival times. The positive predictive value for the 
prediction was highest within the first 5 days of hospital admission. The time to death 
prediction could provide clinically meaningful information for patient care. For example, 
a prognostic test could inform the physician that the patient had a predicted probability of 
death in the next 5 days of 86%, and if the patient did die, the expected time of death 
would be on day 2. Given this information, the treating physician may choose a more 
aggressive treatment strategy. 
Further studies are needed to externally validate our findings and to improve the 
predictive model. Our patient population was comprised of patients with severe sepsis 
from two hospitals in Uganda. The latent factors and endothelial response profiles that we 
identified may be specific to the spectrum of pathogens found in Uganda, and may be 
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different in patient populations with lower HIV prevalence. In particular, the endothelial 
dysfunction profile was associated with MTB bacteremia, which is uncommon in patients 
with severe sepsis in developed countries. The accuracy of our models for predicting 
which patients are at high risk of death and the expected time of death may be improved 
by including other biologic processes known to influence clinical outcome. 
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Appendix 1. Definitions 
Term Criteria 
SIRS* 
2 out of the 4 following criteria: 
Temperature >38°C or < 36°C 
Heart rate >90/min 
Hyperventilation evidenced by respiratory rate >20/min or arterial 
CO2 lower than 32 mmHg 
White blood cell count >12000 cells/ul or lower than 4000 cells/ul 
Sepsis SIRS criteria with presumed or proven infection 
Severe sepsis Sepsis with organ dysfunction 
Septic shock Sepsis with hypotension despite adequate fluid resuscitation 
*SIRS: systemic inflammatory response syndrome 
 
Table A.1. Definitions from the 1991 Consensus Conference
2,5
 
 
 
 
 
Term Criteria 
Sepsis Documented (or suspected) infection with any one of the following 
clinical or laboratory criteria 
General 
parameters 
Fever, hypothermia, tachycardia, tachypnea, altered mental status, 
arterial hypotension, decreased urine output, significant peripheral 
edema, or positive fluid balance 
Inflammatory 
parameters 
Leukocytosis, leukopenia, hyperglycemia, increased C-reactive 
protein, procalcitonin or creatinine, coagulation abnormalities, 
increased cardiac output, reduced mixed venous oxygen saturation 
Hemodynamic 
parameters 
Hypotension, elevated mixed venous oxygen saturation, elevated 
cardiac index 
Organ 
dysfunction 
parameters 
Arterial hypoxemia, acute oliguria, increase in creatinine level, 
elevated international normalized ratio or activated partial 
thromboplastin time, ileus, thrombocytopenia, hyperbilirubinemia 
Tissue perfusion 
parameters 
Hyperlactatemia, decreased capillary refill or mottling 
 
Table A.2. Definition for sepsis from the 2001 Consensus Conference
3,5
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Curriculum Vita 
Education 
Johns Hopkins Bloomberg School of Public Health                                 Baltimore, MD 
Doctor of Philosophy, Epidemiology, Infectious Diseases Concentration              Pending 
Rollins School of Public Health, Emory University                                      Atlanta, GA 
Master of Public Health, International Health, Infectious Diseases Track            05/2004 
Worcester Polytechnic Institute                                                                 Worcester, MA 
Bachelor of Science, Biotechnology and International Studies (Double Major)    05/2002 
Experience 
Naval Medical Research Center, Frederick                                           Frederick, MD 
Principal Investigator, Henry M. Jackson Foundation                            08/2012 – present 
 Served as the Deputy Director and Southeast Asia Regional Director for a program 
aimed at improving clinical outcomes and understanding the pathogenesis of sepsis in 
austere environments.  
 Designed randomized controlled trials and cohort studies of patients with sepsis in 
Uganda, Cambodia, and US Military Treatment Facilities. 
 Managed program implementation, including development and oversight of university 
partnerships, budgets, and statements of work. 
 Engaged and coordinated with a multi-disciplinary team of university, DoD, and US 
government partners.  
Integrated Research Facility (IRF/NIAID/NIH)                                       Frederick, MD 
Clinical Research Portfolio Manager, Lovelace Respiratory Research       9/2010–8/2012 
 Contributed to the development of an international program researching sepsis in low 
resource settings.  
 Designed clinical studies of sepsis and viral hemorrhagic fevers in Africa, with planned 
expansion to South East Asia. 
 Analyzed clinical data to determine prognostic markers indicative of poor sepsis 
outcomes among patients hospitalized in Uganda. 
Walter Reed Army Institute of Research (WRAIR)                           Silver Spring, MD 
Research Lead – Biological Threat Reduction Program (BTRP)           01/2007 – 08/2010 
 Designed and conducted epidemiologic studies in the former Soviet Union primarily 
aiming to define the relative importance of select arthropod-borne and zoonotic 
pathogens, characterize their clinical manifestations, and identify high risk groups. 
 Served as principal investigator on 1 research protocol, project lead on 7 protocols, and 
investigator on an additional 8 protocols. 
 Trained over 100 epidemiologists and clinicians in Georgia, Azerbaijan and Ukraine in 
study design, study procedures, database design, and data analysis. 
 Resided in Azerbaijan to supervise ongoing studies and establish a sustainable 
epidemiologic research capability (2/2008 – 5/2009) 
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Science Officer – BTRP                                                                           03/2006 – 01/2007 
 Worked on a multi-disciplinary team to design and implement a congressionally funded 
program aiming to reduce the threat of biologic agents in the former Soviet Union 
through infectious diseases surveillance and collaborative research.  
 Served as the liaison between the funding organization and teams of epidemiologists, 
entomologists, infectious disease physicians, and microbiologists. 
Lead Surveillance Epidemiologist – BTRP                                              11/2005 – 03/2006 
 Worked closely with institute directors and health professionals in Georgia and 
Azerbaijan to develop surveillance guidelines, including the development of case 
definitions and case report forms. 
 Lead representative on a multi-agency integrated project team formed to coordinate 
training in epidemiology, microbiology, and disease recognition. 
Surveillance Epidemiologist – BTRP                                                       11/2004 – 11/2005 
 Collaborated with host-country health professionals and the Centers for Disease 
Control and Prevention to develop an epidemiology training curriculum. 
 Conducted assessments of the public health systems in Georgia and Azerbaijan. 
Pro-Agua y Desarrollo Integral de Lempira                                   Lempira, Honduras 
Masters Thesis Research, Rollins School of Public Health                  01/2003 – 04/2004 
 Designed and implemented a study evaluating the impact of a water and sanitation 
program in rural Honduras. 
 Assessed hygiene practices, sanitary conditions, bacterial contamination of household 
drinking water, diarrhea prevalence, and anthropometric status of children under five. 
Centers for Disease Control and Prevention                                                 Atlanta, GA 
Research Assistant: HIV/AIDS Branch                                                   09/2002 – 05/2003 
 Worked in a team aiming to engineer a DNA vaccine for HIV-2. 
 Demonstrated ability to design experiments and follow laboratory protocols. 
Abbott Bioresearch Center                                                                        Worcester, MA 
Research Intern: Molecular Biology Department                                   06/2001 – 07/2002 
 Cloned and expressed protein kinases for use in drug specificity assays. 
 Developed laboratory skills in molecular biology techniques such as PCR.    
Armed Forces Research Institute of Medical Sciences                      Bangkok, Thailand 
Major Qualifying Project, Worcester Polytechnic Institute                  12/2001 – 04/2002 
 Designed and conducted a study assessing the economic burden of dengue fever in 
Thailand using Disability Adjusted Life Years (DALYs). 
 Administered over 200 household surveys in the province of Kamphaeng Phet 
examining the direct and indirect costs of illness due to dengue hospitalization. 
 Winner of the Provost’s Major Qualifying Project Award.  
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University of Massachusetts Medical School                                          Worcester, MA 
Major Qualifying Project, Worcester Polytechnic Institute                  09/2001 – 05/2002 
 Worked in the Infectious Diseases and Immunology laboratory at the University of 
Massachusetts Medical Center on a project aiming to understand the role of virus-
specific T lymphocytes in the clinical manifestations of dengue fever. 
 Derived a cell line expressing HLA alleles thought to influence disease severity.  
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